Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabies vaccine (Vero cell) (CpG adjuvanted)
- Development stage
- Preclinical
- Lead developer
- Zhuoyi Biological
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Rabies vaccine (Vero cell) (CpG adjuvanted) is a prophylactic vaccine candidate being developed by Zhuoyi Biological for the prevention of rabies. The vaccine is produced using Vero cell culture technology and is formulated with a CpG oligodeoxynucleotide adjuvant. This adjuvant functions as a Toll-like receptor 9 (TLR9) agonist, which stimulates the innate immune system and enhances the production of type I interferons and pro-inflammatory cytokines. The source context also attributes the mechanism to the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in sensing DNA and mediating immune activation. By combining the rabies antigen with this potent adjuvant, the vaccine aims to provide robust and long-lasting protection against rabies virus infection. It is currently in the IND-enabling or early clinical development stage.
- Other names
- 冻干人用CpG佐剂狂犬病疫苗（Vero细胞）CpG-adjuvanted rabies vaccine (Vero cell)rabies vaccine (Vero cell)-Zhuoyi Biological-STING-prophylactic vaccine-adjuvanted vaccine-Rabies
02
Targets
STING (Stimulator of interferon genes protein)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on rabies vaccine (Vero cell) (CpG adjuvanted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabies vaccine (Vero cell) (CpG adjuvanted).